Picture of Ryvu Therapeutics SA logo

RVU Ryvu Therapeutics SA News Story

0.000.00%
pl flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Brief: Ryvu Therapeutics Initiates Four Phase II Clinical Trials For RVU120

Dec 12 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * INITIATES FOUR PHASE II CLINICAL TRIALS FOR RVU120
    * TRIALS WITHIN BUDGET, FUNDING SECURE UNTIL Q1 2026
    * RVU120 SHOWS FAVORABLE SAFETY PROFILE COMPARED TO OTHER
AML
DRUGS
    * KEY EFFICACY READOUTS FOR RVU120 TRIALS EXPECTED IN H1
2025

Source text:  urn:newsml:reuters.com:*:nEM1WHRhra
Further company coverage:  RVU.WA 

 (Reporting by Gdańsk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

Recent news on Ryvu Therapeutics SA

See all news